A deep-dive strategy guide for pharmaceutical IP teams, portfolio managers, R&D leads, and institutional investors navigating the full lifecycle of […]
The United States pharmaceutical market is undergoing a structural shift that is stripping the profit from traditional drug manufacturing. For
Win the Generic Pricing War: Strategies for Pricing Generic Drugs Read Post »
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of
Connecting Excipients with Drug Patents – New DrugPatentWatch module Read Post »
The biosimilar market is not a niche concern for generic drug manufacturers. It is the central mechanism by which payors,
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited
DrugPatentWatch featured in Inc Magazine Read Post »
Key Takeaways TCO Has Permanently Replaced PPV as the Operating Metric. Purchase Price Variance (PPV) models are inadequate for pharmaceutical
The Cost Structure That Makes AI Non-Optional Bringing a New Molecular Entity (NME) to market costs, on average, US $2.8
1. Executive Strategic Overview The Indian pharmaceutical industry, historically celebrated as the “Pharmacy of the World” for its unparalleled capacity
1. The Opportunity in Numbers: Patent Cliff Sizing and Market Structure Global Market Scale and Growth Trajectory The global generic
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits Read Post »
Get fresh news and insights, drug patent expirations & more…
